Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -43.7% | 60.9% | -10.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.8% | 95.5% | 85.9% | 83.9% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -5.5% | 12.2% | -29.9% | -61.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -38.7% | -12.6% | -57.8% | -77.4% |
| EPS Diluted | -0.1 | -0.07 | -0.21 | -0.32 |
| % Growth | -42.2% | 66.5% | 34.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |